Share these talks and lectures with your colleagues
Invite colleaguesWe noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
Printable Handouts
Navigable Slide Index
- Introduction
- Aim and scope
- Overview of presentation
- Background and context
- Osteoarthritis (OA) (1)
- Osteoarthritis (OA) (2)
- Osteoarthritis (OA) (3)
- Risk factors for OA
- Obesity and OA
- General features of OA
- Loss of homeostasis leads to OA
- The cytokine balance is perturbed in OA
- Repetitive excess mechanical loading
- Synovial, chondral and subchondral changes
- Biomarker: definition
- Rationale for development of OA biomarkers
- The gold standard (radiography) is inadequate
- A better "gold standard"
- Limitations of radiography
- Rationale for identifying early OA biomarkers
- Classification of OA biomarkers: BIPEDs
- Osteoarthritis biomarkers network classification
- OA biomarkers working group
- Classification of OA biomarkers
- Relevance of biomarkers for clinicians & patients
- Relevance to pharmaceutical product pipeline
- The drug pipeline
- Challenges facing the drug pipeline
- The OA drug pipeline
- Surrogate OA biomarkers
- Biochemical marker toolbox in drug discovery
- The biomarker pipeline
- Major classes of OA biomarkers
- Soluble OA biomarkers
- BIPED biomarkers classification
- Classifying biomarkers according to tissue of origin
- Not all biomarkers indicate cartilage catabolism
- The matrisome
- Biomarkers origin: synovial tissues and cells
- Proteomic strategies to identify OA biomarkers
- Differences between OA and RA
- Identification of novel serum OA biomarkers
- Complement proteins as OA biomarkers
- Complement components expression in OA
- Barriers to biomarkers achieving their full potential
- Challenges to OA biomarker discovery
- Performance and measurement of markers
- Summary
- Conclusions (1)
- Conclusions (2)
- Current progress and existing bottlenecks
- Future priorities
- Biomarker combinations
- Biomarkers of joint overuse and injury
- Take home message
- Acknowledgements
Topics Covered
- Diagnosis of osteoarthritis
- Issues with radiographic diagnosis
- Lack of analytical tools and reagents for diagnosis
- Limitations of current biomarkers
- Future opportunities for the pharmaceutical industry
Talk Citation
Mobasheri, A. (2013, January 24). Biomarkers in osteoarthritis [Video file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 19, 2021, from https://hstalks.com/bs/2479/.Publication History
Financial Disclosures
- Dr. Ali Mobasheri has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.